Content about BiondVax

November 7, 2012

A company developing drug-delivery technology based on films inserted into the mouth and a company developing a flu vaccine have entered a deal to combine their products.

WARREN, N.J. — A company developing drug-delivery technology based on films inserted into the mouth and a company developing a flu vaccine have entered a deal to combine their products.

MonoSol Rx on Wednesday announced that it had entered a partnership with Israel-based BiondVax to combine MonoSol's PharmFilm technology with BiondVax's universal flu vaccine, M-001, to create a way to deliver vaccines without needles. MonoSol Rx co-president and CEO A. Mark Schobel said using his company's technology for vaccinations could lead to increased acceptance of flu vaccination.